Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Non-Current Debt: 2023-2025

Historic Non-Current Debt for Inhibrx Biosciences (INBX) over the last 1 years, with Sep 2025 value amounting to $99.9 million.

  • Inhibrx Biosciences' Non-Current Debt was N/A to $99.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.9 million, marking a year-over-year change of. This contributed to the annual value of $207.0 million for FY2023, which is N/A change from last year.
  • As of Q3 2025, Inhibrx Biosciences' Non-Current Debt stood at $99.9 million, which was up 0.64% from $99.3 million recorded in Q2 2025.
  • Over the past 5 years, Inhibrx Biosciences' Non-Current Debt peaked at $207.0 million during Q4 2023, and registered a low of $98.7 million during Q1 2025.
  • For the 2-year period, Inhibrx Biosciences' Non-Current Debt averaged around $126.2 million, with its median value being $99.6 million (2025).